- Cambridge Cognition Holdings
- 08 January 2025 14:25:45
Source: Sharecast
The AIM-traded firm said the results, published in the American Journal of Psychiatry, underscored the significant role of CANTAB in evaluating cognitive function in clinical trials.
It said Cobenfy represents a breakthrough in schizophrenia treatment, being the first drug in decades to target the M1 and M4 muscarinic receptors instead of traditional antipsychotic mechanisms that block dopamine receptors.
The novel approach had demonstrated improved efficacy in reducing both positive and negative symptoms of schizophrenia.
CANTAB digital assessments, known for their precision in measuring cognitive function, enabled Bristol Myers Squibb to conduct a post-hoc analysis of cognitive improvements in patients with pre-specified impairments during the trials, the firm explained.
The results indicated that Cobenfy significantly enhanced cognitive performance.
Cambridge Cognition said it viewed the outcome as a validation of CANTAB's capabilities in enabling targeted study designs and digital data capture technologies.
“This is an important milestone in schizophrenia treatment's history, and we are pleased to have been able to play a part,” said chief operating officer Rob Baker.
“Importantly, this analysis evidences how our digital assessment technologies can streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments in schizophrenia.”
At 1355 GMT, shares in Cambridge Cognition were up 5.25% at 39.47p.
Reporting by Josh White for Sharecast.com.